<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Timolol (ophthalmic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Timolol (ophthalmic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Timolol (ophthalmic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9942" href="/d/html/9942.html" rel="external">see "Timolol (ophthalmic): Drug information"</a> and <a class="drug drug_patient" data-topicid="12321" href="/d/html/12321.html" rel="external">see "Timolol (ophthalmic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9600186"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Betimol;</li>
<li>Istalol;</li>
<li>Timolol Maleate Ocudose;</li>
<li>Timoptic Ocudose;</li>
<li>Timoptic [DSC];</li>
<li>Timoptic-XE [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52870495"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Timop;</li>
<li>JAMP-Timolol;</li>
<li>SANDOZ Timolol;</li>
<li>Timolol Maleate-EX;</li>
<li>Timoptic;</li>
<li>Timoptic-XE</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10536947"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Beta-Adrenergic Blocker</span>;</li>
<li>
<span class="list-set-name">Beta-Adrenergic Blocker, Ophthalmic</span></li></ul></div>
<div class="block don drugH1Div" id="F57105010"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="998f38a3-dbe4-4d25-bac6-3842cd8c347b">Infantile hemangioma, thin and/or superficial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infantile hemangioma, thin and/or superficial: </b>Very limited data available; dosing extrapolated from use in older infants. <b>Note:</b> Premature neonates, patients weighing &lt;2.5 kg, or those with a history of apnea, bradycardia, or chronic lung disease are at a higher risk for systemic adverse effects; use with caution and closely monitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27246751','lexi-content-ref-22256996','lexi-content-ref-27527799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27246751','lexi-content-ref-22256996','lexi-content-ref-27527799'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Ophthalmic gel-forming solution (0.5%) or Ophthalmic solution (timolol maleate 0.5%): Topical: Usual dose: Apply 1 drop to the site of the hemangioma twice daily for 6 to 12 months; higher doses may be needed for larger lesions; however, doses &gt;2 drops/day may increase the risk of systemic absorption; doses of 1 drop 3 times daily or 2 drops twice daily (for larger lesions) have been reported in older infants; consider risk versus benefit and limit dose to lowest necessary to reduce risk of adverse effects. Studies have demonstrated similar efficacy between the solution and gel-forming solution; however, the gel-forming solution is more commonly utilized because the viscosity of the product makes it easier to apply, and it may have lower potential for systemic absorption than the solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26416931','lexi-content-ref-30584062','lexi-content-ref-28771668','lexi-content-ref-27592104','lexi-content-ref-22256996','lexi-content-ref-33825828','lexi-content-ref-28543755','lexi-content-ref-28543755','lexi-content-ref-27527799','lexi-content-ref-30619747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26416931','lexi-content-ref-30584062','lexi-content-ref-28771668','lexi-content-ref-27592104','lexi-content-ref-22256996','lexi-content-ref-33825828','lexi-content-ref-28543755','lexi-content-ref-28543755','lexi-content-ref-27527799','lexi-content-ref-30619747'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F9600260"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Timolol maleate solutions formulated with potassium sorbate (eg, Istalol and AB rated generics) are intended for once-daily administration and are not approved for use in pediatric patients. These products are not interchangeable with other timolol maleate products.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c960c2b-b0bf-4a64-8f51-fdc20ee6b0c9">Glaucoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glaucoma: Note: </b>Use lowest effective dose; the gel formulation may be preferable due to decreased systemic absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213271'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available in infants and children &lt;2 years.</p>
<p style="text-indent:-2em;margin-left:6em;">Gel-forming solution: Ophthalmic: Instill 1 drop (either 0.25% or 0.5% solution) once daily into affected eye(s) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213271','lexi-content-ref-17407363','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213271','lexi-content-ref-17407363','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Solution (timolol maleate): Ophthalmic: Initial: 0.25% solution: Instill 1 drop twice daily into affected eye(s); if response is not adequate, may change to 0.5% solution 1 drop twice daily; maximum dose: 1 drop (0.5% solution)/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4026647','lexi-content-ref-17407363','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4026647','lexi-content-ref-17407363','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="998f38a3-dbe4-4d25-bac6-3842cd8c347b">Infantile hemangioma, thin and/or superficial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infantile hemangioma, thin and/or superficial:</b> Limited data available: Infants and Children: Ophthalmic gel-forming solution (0.5%) or Ophthalmic solution (timolol maleate 0.5%): Topical: Usual dose: Apply 1 to 2 drop(s) to the site of the hemangioma twice daily for 6 to 12 months; 1 drop three times daily has also been reported. Consider risk versus benefit and use lowest dose necessary to cover hemangioma to limit risk of adverse effects. Studies have demonstrated similar efficacy between the solution and gel-forming solution; however, the gel-forming solution is more commonly utilized because the viscosity of the product makes it easier to apply, and it may have lower potential for systemic absorption than the solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26416931','lexi-content-ref-30584062','lexi-content-ref-28771668','lexi-content-ref-22150436','lexi-content-ref-23650294','lexi-content-ref-27592104','lexi-content-ref-22256996','lexi-content-ref-33825828','lexi-content-ref-28543755','lexi-content-ref-27527799','lexi-content-ref-30619747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26416931','lexi-content-ref-30584062','lexi-content-ref-28771668','lexi-content-ref-22150436','lexi-content-ref-23650294','lexi-content-ref-27592104','lexi-content-ref-22256996','lexi-content-ref-33825828','lexi-content-ref-28543755','lexi-content-ref-27527799','lexi-content-ref-30619747'])">Ref</a></span>). <b>Note:</b> A 0.25% timolol gel-forming solution administered as 2 drops twice daily has been shown to be successful in the treatment of periocular infantile hemangiomas (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22410658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22410658'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192755"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51192756"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F9600261"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9942" href="/d/html/9942.html" rel="external">see "Timolol (ophthalmic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60f91e7f-5b7f-4b65-8d79-2634ab361d31">Elevated intraocular pressure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Elevated intraocular pressure:</b>
<b>Ophthalmic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">O<i>pen-angle glaucoma or ocular hypertension</i>
<i>: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Gel-forming solution: Instill 1 drop (either 0.25% or 0.5% solution) once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Solution:</p>
<p style="text-indent:-2em;margin-left:8em;">Once daily timolol maleate formulations (Istalol and AB rated generics): Instill 1 drop (0.5% solution) once daily in the morning.</p>
<p style="text-indent:-2em;margin-left:8em;">Twice daily timolol maleate and hemihydrate formulations (Betimol, Timoptic, and AB rated generics): Instill 1 drop (0.25% solution) into affected eye(s) twice daily; if response is not adequate, increase to 1 drop (0.5% solution) twice daily. May decrease dose to 1 drop once daily if intraocular pressure (IOP) is well controlled.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Angle-closure glaucoma, acute (off-label use)</i>: Instill 1 drop (0.5%) into the affected eye as part of a 4-drug regimen; may repeat in 30 to 60 minutes if IOP remains elevated (eg, &gt;40 mm Hg). <b>Note</b>: Reserve medical management for emergency situations when an assessment by an ophthalmologist will be delayed by ≥1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17910297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17910297'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991660"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988965"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F9600210"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Blurred vision (1% to 33%), burning sensation of eyes (≤38%), stinging of eyes (≤38%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, peripheral edema (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (1% to 5%) xerostomia (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1% to 5%; including anaphylaxis and angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Common cold (1% to 5%), infection (4% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (1% to 5%), dizziness (1% to 5%), headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis (1% to 5%), cataract, conjunctival injection (4% to 10%), conjunctivitis (1% to 5%), corneal staining (1% to 5%), decreased visual acuity (4% to 10%), dry eye syndrome (&gt;5%), epiphora (1% to 5%), erythema of eyelid (&gt;5%), eye discharge (1% to 5%, including crusting), eye discomfort, eye pain (1% to 5%), eye pruritus, foreign body sensation of eye, hyperemia (1% to 5%), keratitis (1% to 5%), lacrimation (1% to 5%), photophobia (1% to 5%), visual disturbance (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory tract infection (1% to 5%; including upper respiratory tract infection), sinusitis (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (Abbas 2020), cardiac arrhythmia, chest pain (Haga 2022), claudication, cold extremity, edema, exacerbation of angina pectoris, heart block (Wang 2019), heart failure (Linkewich 1981), hypotension, palpitations (Walia 2011), Raynaud disease, sick sinus syndrome (Walia 2011), syncope (Abbas 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Muramatsu 2017), exacerbation of psoriasis, pemphigoid-like lesion, psoriasiform eruption</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (Cimolai 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (Cimolai 2019), diarrhea, dyspepsia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (Cimolai 2019), Peyronie disease (Oliphant 2019), retroperitoneal fibrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amnesia (Cimolai 2019), anxiety (Cimolai 2019), cerebral ischemia, cerebrovascular accident, confusion (Cimolai 2019), depression (Cimolai 2019), disorientation (Cimolai 2019), drowsiness (Haga 2022), exacerbation of myasthenia gravis (Cimolai 2019), fatigue (Cimolai 2019), hallucination (Cimolai 2019), insomnia (Cimolai 2019), nightmares (Cimolai 2019), paresthesia (Cimolai 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Systemic lupus erythematosus (Zamber 1992)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharoptosis, choroidal detachment (following filtration surgery), cystoid macular edema, decreased corneal sensitivity, diplopia (Cimolai 2019), error of refraction, eye irritation</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (Cimolai 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, cough (Patel 2015), dyspnea (Haga 2022), interstitial lung disease (Patel 2015), nasal congestion, pulmonary edema, respiratory failure</p></div>
<div class="block coi drugH1Div" id="F9600196"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to timolol or any component of the formulation; bronchial asthma or history of bronchial asthma; severe chronic obstructive pulmonary disease (COPD); sinus bradycardia; second- or third-degree atrioventricular block; overt heart failure; cardiogenic shock</p></div>
<div class="block war drugH1Div" id="F9600208"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse events:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic reactions: Use with caution in patients with history of atopy or a history of severe anaphylaxis to a variety of allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Choroidal detachment: Beta-blockade and/or other aqueous suppressive therapy have been associated with choroidal detachment following filtration procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular disease: Use with caution in cerebrovascular insufficiency; consider alternative therapy for patients with signs/symptoms of decreased cerebral blood flow after therapy initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus (especially labile diabetes); may potentiate hypoglycemia and/or mask signs and symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use with caution in patients with compensated heart failure and monitor for a worsening of the condition; may lead to heart failure in patients without a history of heart failure. Use is contraindicated in overt heart failure. In a scientific statement from the American Heart Association, timolol has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease or other myasthenic symptoms (eg, diplopia, ptosis, and generalized weakness).</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vascular disease (PVD) and Raynaud disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring. Severe respiratory reactions, including fatalities due to bronchospasm in patients with asthma, have been reported with ophthalmic use. Use is contraindicated in bronchial asthma or history of bronchial asthma and severe COPD.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Some products may contain benzalkonium chloride, which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Absorption: Systemic absorption of timolol and adverse effects may occur with ophthalmic use, including respiratory and cardiovascular effects (eg, bradycardia and/or hypotension). Beta-blocker therapy should not be withdrawn abruptly in order to avoid acute tachycardia, hypertension, and/or ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Should not be used alone in angle-closure glaucoma (has no effect on pupillary constriction). Concomitant use of 2 topical beta-blockers is not recommended. Multidose vials have been associated with development of bacterial keratitis; avoid contamination.</p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Timolol <b>maleate</b> products that contain potassium sorbate (eg, Istalol and AB rated generics) are only intended for once daily administration. Products that do <b>not</b> contain potassium sorbate (eg, Timoptic and AB rated generics) are intended for twice daily administration. Products formulated without potassium sorbate are not interchangeable with products formulated with potassium sorbate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: May block systemic effects of beta agonists (eg, epinephrine, norepinephrine); notify anesthesiologist if patient is receiving ophthalmic beta blocker therapy. Patients undergoing planned major surgery should be gradually tapered off therapy (if possible) prior to procedure. If necessary during surgery, effects of beta blocker therapy may be reversed by adrenergic agonists.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878760"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric patients, particularly infants, may attain higher plasma concentrations compared to adults (Coppens 2004; Passo 1984); systemic adverse effects may occur (eg, hypotension, bradycardia, bronchospasm, and apnea); use the lowest effective dose; some experts advocate avoiding the use of ophthalmic beta-blockers in premature and small infants (Moore 2007).</p>
<p style="text-indent:0em;margin-top:2em;">Systemic absorption has been reported following topical use of timolol ophthalmic products when used to treat infantile hemangiomas, which may lead to adverse events, such as hypothermia, hypotension, apnea, and bradycardia, particularly in patients with PMA &lt;44 weeks, weight &lt;2.5 kg, or those with a history of apnea, bradycardia, or chronic lung disease. In addition, use on or near mucosa, sites with thinner skin (eg, perineum), ulcerated hemangiomas, or sites under occlusion may enhance systemic absorption. Risk may be increased with higher doses (eg, &gt;2 drops per day). The risk versus benefit must be weighed for each patient prior to use (AAP [Darrow 2015]; Frommelt 2016; McMahon 2012; Ng 2017; Püttgen 2016).</p></div>
<div class="block foc drugH1Div" id="F9600295"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel Forming Solution, Ophthalmic, as maleate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Timoptic-XE: 0.25% (5 mL [DSC]) [contains tromethamine]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Timoptic-XE: 0.5% (5 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25% (5 mL); 0.5% (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as hemihydrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Betimol: 0.25% (5 mL); 0.5% (5 mL, 10 mL, 15 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as maleate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Istalol: 0.5% (2.5 mL, 5 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Timoptic: 0.25% (5 mL [DSC]); 0.5% (5 mL [DSC], 10 mL [DSC]) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25% (5 mL, 10 mL, 15 mL); 0.5% (2.5 mL, 5 mL, 10 mL, 15 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as maleate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Timolol Maleate Ocudose: 0.5% (60 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Timoptic Ocudose: 0.25% (60 ea); 0.5% (60 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25% (4 ea, 60 ea); 0.5% (1 ea, 4 ea, 60 ea)</p></div>
<div class="block geq drugH1Div" id="F9600189"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9600297"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Betimol Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $33.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $36.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Istalol Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $98.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Timolol Maleate (Once-Daily) Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $64.47 - $70.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Timolol Maleate Ocudose Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per each): $9.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Timolol Maleate Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $0.72 - $3.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $1.31 - $3.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Timolol Maleate PF Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per each): $9.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per each): $9.00 - $9.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Timoptic Ocudose Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per each): $11.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per each): $12.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution gel-forming</b> (Timolol Maleate Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $37.57 - $48.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $41.62 - $53.22</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52870496"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel Forming Solution, Ophthalmic, as maleate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Timolol Maleate-EX: 0.25% (5 mL); 0.5% (5 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Timoptic-XE: 0.5% (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as maleate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Timoptic: 0.5% (5 mL, 10 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25% (5 mL, 10 mL); 0.5% (5 mL, 10 mL)</p></div>
<div class="block admp drugH1Div" id="F52614417"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Administer other topically applied ophthalmic medications at least 10 minutes prior to timolol.</p>
<p style="text-indent:-2em;margin-left:4em;">Wash hands before use; invert closed bottle and shake gel once before use; remove cap carefully so that tip does not touch anything; hold bottle between thumb and index finger; use index finger of other hand to pull down the lower eyelid to form a pocket for the eye drop and tilt head back; place the dispenser tip close to the eye and gently squeeze the bottle to administer 1 drop; remove pressure on bottle after a single drop has been released; <b>do not allow the dispenser tip to touch the eye</b>; replace cap and store bottle in an upright position in a clean area; do <b>not</b> enlarge hole of dispenser; do <b>not</b> wash tip with water, soap, or any other cleaner. Some solutions contain benzalkonium chloride; wait at least 15 minutes after instilling solution before inserting soft contact lenses. With solution, apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration, to decrease systemic absorption of ophthalmic drops (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8100087','lexi-content-ref-6704011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8100087','lexi-content-ref-6704011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Topical: <b>Infantile Hemangioma: </b>Wash hands. Apply drop to hemangioma site area and rub in gently to cover entire hemangioma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22410658','lexi-content-ref-23650294','lexi-content-ref-30619747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22410658','lexi-content-ref-23650294','lexi-content-ref-30619747'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F9600264"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Ophthalmic: For topical ophthalmic use only. Wash hands before use; invert closed bottle and shake gel-forming solutions once before use. Remove contact lenses prior to administration; wait 15 minutes before reinserting if using products containing benzalkonium chloride. In most cases, separate administration of other ophthalmic agents by at least 5 to 10 minutes. When treating acute angle-closure glaucoma, separate administration of other ophthalmic agents by ≥1 minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17910297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17910297'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F9600227"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at controlled room temperature; do not freeze. Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Timoptic in OcuDose: Store in the protective foil wrap and use within 1 month after opening foil package.</p></div>
<div class="block usep drugH1Div" id="F53570768"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension (Timolol gel-forming solution, Timolol maleate <b>without</b> potassium sorbate [eg, Timoptic]: FDA approved in ages ≥2 years and adults; Betimol [timolol hemihydrate], Istalol [timolol maleate <b>with</b> potassium sorbate]: FDA approved in adults); has also been used topically for treatment of infantile hemangioma.</p></div>
<div class="block mst drugH1Div" id="F9600171"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Timolol may be confused with atenolol, Tylenol</p>
<p style="text-indent:-2em;margin-left:4em;">Timoptic may be confused with Betoptic S, Talacen, Viroptic</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Two timolol <b>maleate</b> formulations are available. Products that contain potassium sorbate (eg, Istalol and AB rated generics) are only intended for once daily administration. Products that do <b>not</b> contain potassium sorbate (eg, Timoptic and AB rated generics) are intended for twice daily administration. Products formulated without potassium sorbate are not interchangeable with products formulated with potassium sorbate.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Betimol [US] may be confused with Betanol brand name for metipranolol [Monaco]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9600214"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F9600215"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: Beta-Blockers may enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Timolol (Ophthalmic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Beta-Blockers may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose. Increase monitoring for clinical response and adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Beta-Blockers may diminish the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Beta-Blockers (Nonselective) may enhance the hypertensive effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may diminish the therapeutic effect of Etilefrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etofylline: Beta-Blockers may diminish the therapeutic effect of Etofylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers.  Management: Consider alternatives to either grass pollen allergen extract (5 grass extract) or beta-blockers in patients with indications for both agents.  Canadian product labeling specifically lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Beta-Blockers may diminish the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Beta-Blockers may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Beta-Blockers may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: May enhance the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May enhance the bradycardic effect of Beta-Blockers. Reserpine may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Beta-Blockers may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Sulfonylureas. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: Beta-Blockers may diminish the therapeutic effect of Tasimelteon.  Management: Consider avoiding nighttime administration of beta-blockers during tasimelteon therapy due to the potential for reduced tasimelteon efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">White Birch Allergen Extract: Beta-Blockers may enhance the adverse/toxic effect of White Birch Allergen Extract. Specifically, beta-blockers may reduce the effectiveness of beta-agonists that may be required to treat systemic reactions to white birch allergen extract. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F9600192"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Decreased fetal heart rate has been observed following maternal use of ophthalmic timolol during pregnancy (Wagenvoort 1998). Timolol is absorbed systemically following ophthalmic use; additional adverse effects observed with systemic administration may occur.</p>
<p style="text-indent:0em;margin-top:2em;">If ophthalmic agents are needed to treat glaucoma in pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease exposure to the fetus (Johnson 2001; Salim 2014; Wagenvoort 1998).</p></div>
<div class="block mopp drugH1Div" id="F53570767"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic/topical: Monitor for systemic beta-blocker effects, including bradycardia, hypotension, hypoglycemia, hypothermia, shortness of breath/bronchospasm, apnea, and sleep disturbance (especially in younger patients).</p>
<p style="text-indent:-2em;margin-left:4em;">Infantile hemangioma: If treating larger or ulcerated hemangiomas, monitor heart rate 2 to 4 hours after topical application (Weibel 2016). For premature and low-birth-weight infants, closely monitor temperature, BP, apnea, and heart rate at initiation and throughout therapy with topical timolol (Frommelt 2016; McMahon 2012).</p></div>
<div class="block pha drugH1Div" id="F9600228"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Blocks both beta-1 and beta-2 adrenergic receptors and reduces intraocular pressure by reducing aqueous humor production or possibly increasing the outflow of aqueous humor.</p>
<p style="text-indent:-2em;margin-left:2em;">The exact mechanism of beta-blockers for infantile hemangiomas is unclear, but is hypothesized to be related to vasoconstriction, angiogenesis inhibition, growth factor inhibition, and induction of apoptosis (Bhat 2016).</p></div>
<div class="block phk drugH1Div" id="F9600230"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Solution:</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Intraocular pressure reduction: 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Timolol is measurable in the serum following ophthalmic use. Timolol has been detected in the blood and urine of some infants who were treated topically for infantile hemangiomas (Weibel 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 4 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962008"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apimol | Cusimolol | Nyolol | Ocumol | Oftan timolol | Ophtamolol | Optimol | Timo-comod | Timoptol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bio eyes timo | Glatim | Klonalol | Ofal | Plostim | Poentimol | Proflax | Proflax-Xe | Protevis | Timoder | Timoler | Timolol denver farma | Timolol dorf | Timolol max vision | Timolpres | Timoptic | Zopirol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dispatim | Timabak | Timo comod | Timoftal | Timogel | Timohexal | Timolol | Timolol novartis | Timoptic</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nyogel | Optimol | Tenopt | Timoptol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aristomol | Gemolol | Intramol | Lotensin | Meloptol | Nyolol | Temlo | Timocare | Timodrop | Timolat | Timolol | Timolol apex | Timomin | Xilol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Geltim | Nyogel | Nyolol | Timabak | Timo comod | Timo-Pos | Timolol | Timoptol</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Normoptic</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Arutimol | Cusimolol | Glaumol | Glucomol | Nyolol | Oftan timolol | Timolol | Timolol Rph | Timolol Vision | Timoptic | Unitimolol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Glaucotrat | Glautimol | Maleato de timolol | Nyolol | Tenoftal | Timabak | Timolol | Timoneo | Timoptol | Timosan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nyolol | Timo comod | Timogel | Timolol "fermic" | Timoptic</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Glausolets | Glautimol | Nyolol | Oculix | Timabak | Timolol | Timop | Timoptol | Tiof</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cheng rui | Timolol | Timoptol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Glaucofin | Glaucomicron | Glaucopharm | Globitan | Imot Ofteno | Lolomit | Matimof | Nyolol | Ofepress | Oftabet | Oftalmotrilol | Ophthamolol | Optimol | Prestiblock | Syvimol | Timol-oft | Timolet | Timolol | Timolol maleato | Timopres | Timoptol | Timoptol xe | Wassertim</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo timoptol | Arutimol | Ocupres E | Oftan timolol | Oftensin | Timo comod | Timohexal | Timolol | Timolol pos | Timoptol | Uni timolol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Arutimol | Dispatim | Nyogel | Tim-ophtal | Timo comod | Timo Vision | Timo-comod | Timogel | Timohexal | Timolol | Timolol AT 1A Pharma | Timolol cv | Timolol micro labs | Timolol pos | Timomann | Uniget-xe</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Imolgrin | Imot Ofteno | Neo timol | Nyolol | Oculpres | Oculpres 0.5% sc | Timolol | Timoptic | Timoptol | Tiof</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Citol timolol | Imot | Imot Ofteno | Mioticox | Nyolol | Poentimol | Timoptol | Timox | Tiof</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Arutimol | Nyolol | Oftan timolol | Timohexal | Timoptic | Timosan | Unitimolol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Nyolol | Timogel | Timolol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Nyolol | Timabak | Timoftol | Timogel</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Biolal | Epitimol | Lopres | Timolol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aquanil | Blocanol | Ocubloc | Oftan-timolol | Timolol alcon | Timosan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Digaol | Gaoptol | Geltim lp | Nyogel lp | Nyolol | Timabak | Timocomod | Timolol | Timolol alcon | Timolol chauvin | Timolol g gam | Timolol Sandoz | Timolol teva | Timoptol | Timoptol lp</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eysano | Glau opt | Nyogel | Timolol | Timolol almus | Timolol cox | Timolol kent | Timolol Sandoz | Timoptol | Timoptol la | Tiopex</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Epitimol | Lavimol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Geltim | Glafemak | Lithimole | Nyogel | Nyolol | Temserin | Thilotim | Waucosin | Yesan</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Alfer lolo</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo timop | Europtic | Nyolol | Oftan timolol | Ophtamolol | Optimol | Timabak | Timo-comod | Timolol | Timolol maleate alcon | Timolol Martindale | Timoptol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Timalen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Arutimol | Cusimolol | Huma-timolol | Oftan timolol | Timoptic</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Glaucopress | Isotic adretor | Kentimol | Nyolol | Opthil | Opticom | Tim-ophtal | Timol | Timolol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Nyogel | Timoptol | Timoptol la</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Apotil | Nyolol | Tiloptic | Timolol | V-Optic</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Flocipron | Glaucare | Gluc aid | Glucomol | Glucomol-od | Glucotim | Glucotim LA | Gludrop | Glunil | Glutim | Iotim | Lopres | Nyolol | Oclean | Oculan | Ocupres | Ocutim | Opteze | Siotim | Timanol | Timdus | Timlol pf | Timo-5 | Timoblu | Timol | Timolast | Timolen | Timolet | Timolet-p | Timolong | Timopress | Timoptal | Timorite | Timostar | Timowa | Timozen</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Tilol</span>;</li>
<li>
<span class="countryCode">(IR)</span> <span class="country">Iran, Islamic Republic of</span><span class="countrySeparator">: </span><span class="drugName">Timolin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Droptimol | Nyogel | Oftimolo | Omkipo | Timod | Timogel | Timolabak | Timololo | Timolux | Timoptol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Apimol | Cusimolol | Nyolol | Ophtalmolol | Timolol | Timoptol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Brunne | Phartimo | Phartimo mita | Phartimo nidek | Rysmon | Rysmon tg | Rysmon wakamoto | Thiaboot | Timabak | Timoleate | Timoleate pf | Timolol | Timolol pf nitten | Timolol wakamoto | Timoptol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Akutim | Aurotim | Glucotim | Iotim | Ivytimol | Occumol | Timolet od | Timoptol | Tml</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Interalol | Nyolol | Rysmon tg | Timabak | Timo-comod | Timogla | Timolen | Timolol | Timolux | Timoptic | Timoptic-xe | Unitimo</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Nyolol | Oftan timolol | Optimol | Timabak | Timo comod | Timoptol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Digaol | Lithimole | Nyolol | Timabak | Timoptol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo timop | Apo timoptol | Arutimol | End-timololis | Glucomol | Nyolol | Ocupres | Oftan timolol | Oftensin | Tim-ophtal | Timogel | Timohexal | Timolol | Timolol alcon | Timolol micro labs | Timoptic | Timoptol | Timosan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dispatim | Geltim | Nyogel | Timabak | Timo comod | Timo-Pos | Timohexal | Timolol falcon | Timoptol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apo timop | Apo timoptol | Arutimol | Nyolol | Ocupres | Oftan timolol | Oftensin | Optimol | Timohexal | Timoptic | Timosan | Unitimolol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Timabak | Timo comod | Timo-comod | Timolol pos | Timoptol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Horex | Imot Ofteno | Nyolol | Profloxtec | Shemol | Tenglamol | Ticromic | Timatimsun | Timolol | Timolol Diba | Timolol maleato Kener | Timoptol | Timozzard | Tiof | Zinhypoc</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Iotim | Nyolol | Optimol | Timo comod | Timo-comod | Timolol pos | Timoptol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Aristomol | Bymol | Drumoptol | Ethimol | Hovid timolol | Iotim 0.5% eye drops | Ivytimol | Timomed | Timosol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Loptomit | Nyogel | Timo-comod | Timogel | Timolol | Timolol Alpharma | Timoptol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aquanil | Blocadren | Blocadren depot | Oftamolol | Oftan | Timoptol la | Timosan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo timop | Arrow Timolol | Gen-Timolol | Timoptol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Betamol | Betamolol | Glaucolip | Globitan | Imot Ofteno | Nyolol | Optimol | Timofta | Timolol | Timolol carrion | Timolol-wasser | Timoptic | Timoptol | Timox | Tiof | Vistol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Celsus Timolol Maleate | I Supres | Intramol | Normopres | Nyolol | Ocupres | Oftan | Optaluz | Optamol | Timabak | Timanol | Timoptol | Timostal | Vendizol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Altim | Blotim | Dytim | Hioptal | Nyolol | Ocutim | Optim | Optimol | Optipress | Timentin | Timol | Timoptic | Timoptol | Timosol | Timotek</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Nyolol | Oftan timolol | Oftensin | Timo comod | Timohexal | Timolol pos | Timoptic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Betimol | Istalol | Timoptic</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Nyogel | Nyolol | Timabak | Timogel | Timolol chauvin | Timoptol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Citol timolol | Ileton | Nyolol | Oftalmol timolol | Plostim | Poentimol | Proflax | Timolol biosano | Timolol chile | Tiof</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apimol | Cusimolol | Nyolol Gel | Ocumol | Optimol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Glaumol | Glucomol | Ocupres E | Oftan timolol | Ophtamolol | Timabak | Timo comod | Timorom | Unitimolol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Arutimol | Cusimolol | Glaumol | Glautam | Glimol | Glymol | Niolol | Nyolol | Ocucer | Ocumed | Ocumol | Ocupres - e | Ocuryl | Ocutim | Oftan Timogel | Oftan timolol | Oftensin | Optimol | Rotima | Timadren | Timohexal | Timolol | Timolol acos | Timolol akos | Timolol betalek | Timolol dia | Timolol lens | Timolol Mez | Timolol pos | Timolol solopharm | Timolol teva | Timolollong | Timoptic</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apimol | Cusimolol | Nyolol | Ocumol | Ophtamolol | Optimol | Timoptol | Tunolol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aquanil | Blocadren | Optimol | Timolol alcon | Timolol ccs | Timolol novartis | Timosan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo timop | Cusimolol | Nyolol | Tiamol | Timabak | Timo comod | Timolol | Timolol maleate alcon | Timoptol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Metablen | Nyolol | Timalen | Timoptic</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Arutimol | Nyolol | Timohexal | Timolol | Timoptic timoptol | Timoptol | Unitimolol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Archimol | Glauco oph | Glucotim | Intramol | Nyolol | Oftan timolol | Opsartimol | Timo mac | Timo-optal | Timodrop | Timolens | Timoptol | Timosil</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Intramol | Normoptic | Nyolol | Tunolol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Normatin | Nyolol | Timabak | Timo comod | Timo-comod | Timocopt | Timoftal | Timolol | Timoptic | Timosol | Timotem</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Delolol | Himitan | Nyolol | Oftan timolol | Timin | Timo comod | Timohexal | Timol | Timolast | Timolol | Timoptol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Arutimol | Cusimolol | Iotim | Niolol | Normatin | Ocupres E | Ocuryl | Oftan timolol | Oftimol | Timohexal | Timolol | Timoptic | Timoptol | Unitimolol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ablol | Aurotim | Cusimolol | Iotim | Ivytimol | Timosol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Beyonas timolol | Glautimol | Nyolol | Optifarm | Optimof | Plostim | Proflax | Proflax-Xe | Tensoprel | Timolol | Tiof</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Globitan | Imot Ofteno | Matigel | Matilol | Nyolol | Timolol | Timolol maleato | Timoptol | Timox</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Glaucosan | Nyogel | Occumol | Timolol | Timoptol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cusimolol | Ivytimol | Ocupres</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Iotim | Occumol | Oculan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32292680">
<a name="32292680"></a>Abbas SA, Hamadani SM, Ahmad U, Desai A, Kitchloo K. Ophthalmic timolol and hospitalization for symptomatic bradycardia and syncope: a case series. <i>Cureus</i>. 2020;12(3):e7270. doi:10.7759/cureus.7270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/32292680/pubmed" id="32292680" target="_blank">32292680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thea.1">
<a name="Thea.1"></a>Betimol (timolol) [prescribing information]. Lexington, MA: Thea Pharma Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27057498">
<a name="27057498"></a>Bhat YJ, Yaseen A, Hassan I. Topical timolol maleate: an effectual and safe recourse for infantile hemangiomas. <i>Indian Dermatol Online J</i>. 2016;7(2):124-125. doi:10.4103/2229-5178.178076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/27057498/pubmed" id="27057498" target="_blank">27057498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28771668">
<a name="28771668"></a>Borok J, Gangar P, Admani S, Proudfoot J, Friedlander SF. Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial. <i>Br J Dermatol</i>. 2018;178(1):e51-e52. doi:10.1111/bjd.15865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/28771668/pubmed" id="28771668" target="_blank">28771668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22150436">
<a name="22150436"></a>Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. <i>Pediatr Dermatol</i>. 2012;29(1):28-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/22150436/pubmed" id="22150436" target="_blank">22150436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22410658">
<a name="22410658"></a>Chambers CB, Katowitz WR, Katowitz JA, Binenbaum G. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. <i>Ophthal Plast Reconstr Surg</i>. 2012;28(2):103-106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/22410658/pubmed" id="22410658" target="_blank">22410658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23650294">
<a name="23650294"></a>Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. <i>Pediatrics</i>. 2013;131(6):e1739-1747.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/23650294/pubmed" id="23650294" target="_blank">23650294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462538">
<a name="31462538"></a>Cimolai N. Neuropsychiatric Adverse events from topical ophthalmic timolol. <i>Clin Med Res</i>. 2019;17(3-4):90-96. doi:10.3121/cmr.2019.1486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/31462538/pubmed" id="31462538" target="_blank">31462538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213271">
<a name="19213271"></a>Coppens G, Stalmans I, Zeyen T, et al, "The Safety and Efficacy of Glaucoma Medication in the Pediatric Population," <i>J Pediatr Ophthalmol Strabismus</i>, 2009, 46(1):12-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/19213271/pubmed" id="19213271" target="_blank">19213271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27592104">
<a name="27592104"></a>Danarti R, Ariwibowo L, Radiono S, Budiyanto A. Topical timolol maleate 0.5% for infantile hemangioma: its effectiveness compared to ultrapotent topical corticosteroids - a single-center experience of 278 cases. <i>Dermatology</i>. 2016;232(5):566-571. doi:10.1159/000448396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/27592104/pubmed" id="27592104" target="_blank">27592104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26416931">
<a name="26416931"></a>Darrow DH, Greene AK, Mancini AJ, Nopper AJ; SECTION ON DERMATOLOGY, SECTION ON OTOLARYNGOLOGY–HEAD AND NECK SURGERY, and SECTION ON PLASTIC SURGERY. Diagnosis and management of infantile hemangioma. <i>Pediatrics</i>. 2015;136(4):e1060-e1104. doi:10.1542/peds.2015-2485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/26416931/pubmed" id="26416931" target="_blank">26416931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27246751">
<a name="27246751"></a>Frommelt P, Juern A, Siegel D, et al. Adverse events in young and preterm infants receiving topical timolol for infantile hemangioma. <i>Pediatr Dermatol</i>. 2016;33(4):405-414. doi:10.1111/pde.12869<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/27246751/pubmed" id="27246751" target="_blank">27246751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35154926">
<a name="35154926"></a>Haga C, Waller T, Ahuja AS, Farford B, Dawson N, Yin M. There's danger in the drops: systemic effects of ophthalmic drops used to treat glaucoma. <i>Cureus</i>. 2022;14(1):e20945. doi:10.7759/cureus.20945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/35154926/pubmed" id="35154926" target="_blank">35154926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4026647">
<a name="4026647"></a>Hoskins HD Jr, Hetherington J Jr, Magee SD, Naykhin R, Migliazzo CV. Clinical experience with timolol in childhood glaucoma. <i>Arch Ophthalmol</i>. 1985;103(8):1163-1165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/4026647/pubmed" id="4026647" target="_blank">4026647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bausch.1">
<a name="Bausch.1"></a>Istalol (timolol) [prescribing information]. Tampa, FL: Bausch &amp; Lomb Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11274697">
<a name="11274697"></a>Johnson SM, Martinez M, and Freedman S, "Management of Glaucoma in Pregnancy and Lactation," <i>Surv Ophthalmol</i>, 2001, 45(5):449-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/11274697/pubmed" id="11274697" target="_blank">11274697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30584062">
<a name="30584062"></a>Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. <i>Pediatrics</i>. 2019;143(1):e20183475. doi:10.1542/peds.2018-3475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/30584062/pubmed" id="30584062" target="_blank">30584062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7282702">
<a name="7282702"></a>Linkewich JA, Herling IM. Bradycardia and congestive heart failure associated with ocular timolol maleate. <i>Am J Hosp Pharm</i>. 1981;38(5):699-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/7282702/pubmed" id="7282702" target="_blank">7282702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18552619">
<a name="18552619"></a>Madadi P, Koren G, Freeman DJ, et al, "Timolol Concentrations in Breast Milk of a Woman Treated for Glaucoma: Calculation of Neonatal Exposure," <i>J Glaucoma</i>, 2008, 17(4):329-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/18552619/pubmed" id="18552619" target="_blank">18552619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22256996">
<a name="22256996"></a>McMahon P, Oza V, Frieden IJ. Topical timolol for infantile hemangiomas: putting a note of caution in "cautiously optimistic." <i>Pediatr Dermatol</i>. 2012;29(1):127-130. doi:10.1111/j.1525-1470.2011.01685.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/22256996/pubmed" id="22256996" target="_blank">22256996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17407363">
<a name="17407363"></a>Moore W, Nischal KK. Pharmacologic management of glaucoma in childhood. <i>Paediatr Drugs</i>. 2007;9(2):71-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/17407363/pubmed" id="17407363" target="_blank">17407363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33825828">
<a name="33825828"></a>Muñoz-Garza FZ, Ríos M, Roé-Crespo E, et al. Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage: a randomized clinical trial. <i>JAMA Dermatol</i>. 2021;157(5):583-587. doi:10.1001/jamadermatol.2021.0596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/33825828/pubmed" id="33825828" target="_blank">33825828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27545615">
<a name="27545615"></a>Muramatsu K, Nomura T, Shiiya C, Nishiura K, Tsukinaga I. Alopecia induced by timolol eye-drops. <i>Acta Derm Venereol</i>. 2017;97(2):295-296. doi:10.2340/00015555-2520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/27545615/pubmed" id="27545615" target="_blank">27545615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543755">
<a name="28543755"></a>Ng MSY, Tay YK, Ng SS, Foong AYW, Koh MJ. Comparison of two formulations of topical timolol for the treatment of infantile hemangiomas. <i>Pediatr</i>
<i>Dermatol</i>. 2017;34(4):492-493. doi:10.1111/pde.13167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/28543755/pubmed" id="28543755" target="_blank">28543755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29423783">
<a name="29423783"></a>Oliphant H, Gouws P. Peyronie's disease and Dupuytren's contracture secondary to topical timolol. <i>Int Ophthalmol</i>. 2019;39(3):683-685. doi:10.1007/s10792-018-0837-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/29423783/pubmed" id="29423783" target="_blank">29423783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6514303">
<a name="6514303"></a>Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. <i>Ophthalmology</i>. 1984;91(11):1361-1363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/6514303/pubmed" id="6514303" target="_blank">6514303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26236595">
<a name="26236595"></a>Patel H, Wilches LV, Guerrero J. Timolol-induced interstitial lung disease. <i>Respir Med Case Rep</i>. 2015;15:30-32. doi:10.1016/j.rmcr.2015.02.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/26236595/pubmed" id="26236595" target="_blank">26236595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31437034">
<a name="31437034"></a>Paul SP, Davis RF. Infantile haemangioma: topical timolol gel may be safer in premature babies. <i>Br J Hosp Med (Lond)</i>. 2019;80(8):i. doi:10.12968/hmed.2019.80.8.i<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/31437034/pubmed" id="31437034" target="_blank">31437034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17910297">
<a name="17910297"></a>Pokhrel PK, Loftus SA. Ocular emergencies [published correction appears in: <i>Am Fam Physician</i>. 2008;77(7):920]. <i>Am Fam Physician</i>. 2007;76(6):829-836.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/17910297/pubmed" id="17910297" target="_blank">17910297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27527799">
<a name="27527799"></a>Püttgen K, Lucky A, Adams D, et al; Hemangioma Investigator Group. Topical timolol maleate treatment of infantile hemangiomas. <i>Pediatrics</i>. 2016;138(3):e20160355. doi:10.1542/peds.2016-0355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/27527799/pubmed" id="27527799" target="_blank">27527799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24469077">
<a name="24469077"></a>Salim S. Glaucoma in pregnancy. <i>Curr Opin Ophthalmol</i>. 2014;25(2):93-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/24469077/pubmed" id="24469077" target="_blank">24469077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903673">
<a name="2903673"></a>Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/2903673/pubmed" id="2903673" target="_blank">2903673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Timoptic.2">
<a name="Timoptic.2"></a>Timoptic (timolol maleate) [prescribing information]. Bridgewater, NJ: Bausch &amp; Lomb Americas Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Timoptic.1">
<a name="Timoptic.1"></a>Timoptic Ocudose (timolol maleate) [prescribing information]. Bridgewater, NJ: Bausch &amp; Lomb Americas Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Timoptic-XE.1">
<a name="Timoptic-XE.1"></a>Timoptic-XE (timolol maleate) [prescribing information]. Tampa, FL: Bausch &amp; Lomb Incorporated; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8100087">
<a name="8100087"></a>Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/8100087/pubmed" id="8100087" target="_blank">8100087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9894675">
<a name="9894675"></a>Wagenvoort AM, van Vugt JM, Sobotka M, et al, “Topical Timolol Therapy in Pregnancy: Is It Safe for the Fetus?” <i>Teratology</i>, 1998, 58(6):258-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/9894675/pubmed" id="9894675" target="_blank">9894675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22025865">
<a name="22025865"></a>Walia HS, Walia SS, Emanuel ME. Sick sinus syndrome associated with topical timolol maleate instillation. <i>J Pharmacol Pharmacother</i>. 2011;2(4):300-302. doi:10.4103/0976-500X.85946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/22025865/pubmed" id="22025865" target="_blank">22025865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31791399">
<a name="31791399"></a>Wang Z, Denys I, Chen F, et al. Complete atrioventricular block due to timolol eye drops: a case report and literature review. <i>BMC Pharmacol Toxicol</i>. 2019;20(1):73. doi:10.1186/s40360-019-0370-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/31791399/pubmed" id="31791399" target="_blank">31791399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26840644">
<a name="26840644"></a>Weibel L, Barysch MJ, Scheer HS, et al. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. <i>Pediatr</i>
<i>Dermatol</i>. 2016;33(2):184-190. doi:10.1111/pde.12767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/26840644/pubmed" id="26840644" target="_blank">26840644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30619747">
<a name="30619747"></a>Wu HW, Wang X, Zhang L, Zheng JW, Liu C, Wang YA. Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. <i>Front</i>
<i>Oncol</i>. 2018;8:605. doi:10.3389/fonc.2018.00605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/30619747/pubmed" id="30619747" target="_blank">30619747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1404139">
<a name="1404139"></a>Zamber RW, Starkebaum G, Rubin RL, Martens HF, Wener MH. Drug induced systemic lupus erythematosus due to ophthalmic timolol. <i>J Rheumatol</i>. 1992;19(6):977-979.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/1404139/pubmed" id="1404139" target="_blank">1404139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6704011">
<a name="6704011"></a>Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984;102(4):551-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/6704011/pubmed" id="6704011" target="_blank">6704011</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16056 Version 474.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
